AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. ONC
  4. [Form 4] BeOne Medicines Ltd. American Insider Trading Activity

[Form 4] BeOne Medicines Ltd. American Insider Trading Activity

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

BeOne Medicines (ONC) filed a routine Form 4 disclosing that Director and Scientific Advisory Board Chair Xiaodong Wang sold an aggregate 2,007 American Depositary Shares (each equal to 13 ordinary shares) on 06/24/2025 under a Rule 10b5-1 plan at prices ranging from $263.40&苍产蝉辫;鈥�&苍产蝉辫;$267.81. The total consideration is roughly $0.53 million, representing about 0.3 % of his total beneficial ownership. No new grants, derivative transactions, or governance changes were reported.

BeOne Medicines (ONC) ha presentato un modulo di routine Form 4, rivelando che il Direttore e Presidente del Comitato Scientifico, Xiaodong Wang, ha venduto complessivamente 2.007 American Depositary Shares (ognuna equivalente a 13 azioni ordinarie) il 24/06/2025, secondo un piano Rule 10b5-1, a prezzi compresi tra 263,40 e 267,81 dollari. Il valore totale della transazione 猫 di circa 0,53 milioni di dollari, pari a circa lo 0,3% della sua partecipazione totale. Non sono state segnalate nuove assegnazioni, operazioni su derivati o cambiamenti nella governance.

BeOne Medicines (ONC) present贸 un Formulario 4 rutinario revelando que el Director y Presidente del Consejo Asesor Cient铆fico, Xiaodong Wang, vendi贸 un total de 2,007 American Depositary Shares (cada una equivalente a 13 acciones ordinarias) el 24/06/2025 bajo un plan Rule 10b5-1, a precios que oscilaron entre $263.40 y $267.81. La contraprestaci贸n total es aproximadamente $0.53 millones, representando alrededor del 0.3 % de su propiedad beneficiosa total. No se reportaron nuevas concesiones, transacciones con derivados ni cambios en la gobernanza.

BeOne Medicines (ONC)電� 鞝曣赴 Form 4毳� 鞝滌稖頃橃棳 鞚挫偓 瓴� 瓿柬暀 鞛愲 鞙勳洂須� 鞚橃灔 Xiaodong Wang鞚� 2025雲� 6鞗� 24鞚� Rule 10b5-1 瓿勴殟鞐� 霐半澕 齑� 2,007臧滌潣 氙戈淡 鞓堩儊 歃濎劀(臧侁皝 氤错喌欤� 13欤检棎 頃措嫻)毳� $263.40鞐愳劀 $267.81 靷澊鞚� 臧�瓴╈溂搿� 毵る弰頄堧嫟瓿� 瓿奠嫓頄堨姷雼堧嫟. 齑� 瓯半灅 旮堨暋鞚� 鞎� 53毵� 雼煬搿�, 攴胳潣 鞝勳泊 鞁れ 靻岇湢 歆�攵勳潣 鞎� 0.3%鞐� 頃措嫻頃╇媹雼�. 靸堧鞖� 攵�鞐�, 韺岇儩靸來拡 瓯半灅 霕愲姅 瓯半矂雱岇姢 氤�瓴� 靷暛鞚� 氤搓碃霅橃 鞎婌晿鞀惦媹雼�.

BeOne Medicines (ONC) a d茅pos茅 un formulaire 4 de routine r茅v茅lant que le directeur et pr茅sident du comit茅 consultatif scientifique, Xiaodong Wang, a vendu un total de 2 007 American Depositary Shares (chacune 茅quivalente 脿 13 actions ordinaires) le 24/06/2025 dans le cadre d鈥檜n plan Rule 10b5-1, 脿 des prix allant de 263,40 $ 脿 267,81 $. La contrepartie totale s鈥櫭﹍猫ve 脿 environ 0,53 million de dollars, repr茅sentant environ 0,3 % de sa participation b茅n茅ficiaire totale. Aucune nouvelle attribution, transaction sur d茅riv茅s ou changement de gouvernance n鈥檃 茅t茅 signal茅.

BeOne Medicines (ONC) hat ein routinem盲脽iges Formular 4 eingereicht und offengelegt, dass der Direktor und Vorsitzende des Wissenschaftlichen Beirats, Xiaodong Wang, am 24.06.2025 insgesamt 2.007 American Depositary Shares (jeweils gleich 13 Stammaktien) im Rahmen eines Rule 10b5-1-Plans zu Preisen zwischen 263,40 und 267,81 US-Dollar verkauft hat. Die Gesamtsumme bel盲uft sich auf etwa 0,53 Millionen US-Dollar, was etwa 0,3 % seines gesamten wirtschaftlichen Eigentums entspricht. Es wurden keine neuen Zuteilungen, Derivatgesch盲fte oder 脛nderungen in der Unternehmensf眉hrung gemeldet.

Positive
  • None.
Negative
  • None.

BeOne Medicines (ONC) ha presentato un modulo di routine Form 4, rivelando che il Direttore e Presidente del Comitato Scientifico, Xiaodong Wang, ha venduto complessivamente 2.007 American Depositary Shares (ognuna equivalente a 13 azioni ordinarie) il 24/06/2025, secondo un piano Rule 10b5-1, a prezzi compresi tra 263,40 e 267,81 dollari. Il valore totale della transazione 猫 di circa 0,53 milioni di dollari, pari a circa lo 0,3% della sua partecipazione totale. Non sono state segnalate nuove assegnazioni, operazioni su derivati o cambiamenti nella governance.

BeOne Medicines (ONC) present贸 un Formulario 4 rutinario revelando que el Director y Presidente del Consejo Asesor Cient铆fico, Xiaodong Wang, vendi贸 un total de 2,007 American Depositary Shares (cada una equivalente a 13 acciones ordinarias) el 24/06/2025 bajo un plan Rule 10b5-1, a precios que oscilaron entre $263.40 y $267.81. La contraprestaci贸n total es aproximadamente $0.53 millones, representando alrededor del 0.3 % de su propiedad beneficiosa total. No se reportaron nuevas concesiones, transacciones con derivados ni cambios en la gobernanza.

BeOne Medicines (ONC)電� 鞝曣赴 Form 4毳� 鞝滌稖頃橃棳 鞚挫偓 瓴� 瓿柬暀 鞛愲 鞙勳洂須� 鞚橃灔 Xiaodong Wang鞚� 2025雲� 6鞗� 24鞚� Rule 10b5-1 瓿勴殟鞐� 霐半澕 齑� 2,007臧滌潣 氙戈淡 鞓堩儊 歃濎劀(臧侁皝 氤错喌欤� 13欤检棎 頃措嫻)毳� $263.40鞐愳劀 $267.81 靷澊鞚� 臧�瓴╈溂搿� 毵る弰頄堧嫟瓿� 瓿奠嫓頄堨姷雼堧嫟. 齑� 瓯半灅 旮堨暋鞚� 鞎� 53毵� 雼煬搿�, 攴胳潣 鞝勳泊 鞁れ 靻岇湢 歆�攵勳潣 鞎� 0.3%鞐� 頃措嫻頃╇媹雼�. 靸堧鞖� 攵�鞐�, 韺岇儩靸來拡 瓯半灅 霕愲姅 瓯半矂雱岇姢 氤�瓴� 靷暛鞚� 氤搓碃霅橃 鞎婌晿鞀惦媹雼�.

BeOne Medicines (ONC) a d茅pos茅 un formulaire 4 de routine r茅v茅lant que le directeur et pr茅sident du comit茅 consultatif scientifique, Xiaodong Wang, a vendu un total de 2 007 American Depositary Shares (chacune 茅quivalente 脿 13 actions ordinaires) le 24/06/2025 dans le cadre d鈥檜n plan Rule 10b5-1, 脿 des prix allant de 263,40 $ 脿 267,81 $. La contrepartie totale s鈥櫭﹍猫ve 脿 environ 0,53 million de dollars, repr茅sentant environ 0,3 % de sa participation b茅n茅ficiaire totale. Aucune nouvelle attribution, transaction sur d茅riv茅s ou changement de gouvernance n鈥檃 茅t茅 signal茅.

BeOne Medicines (ONC) hat ein routinem盲脽iges Formular 4 eingereicht und offengelegt, dass der Direktor und Vorsitzende des Wissenschaftlichen Beirats, Xiaodong Wang, am 24.06.2025 insgesamt 2.007 American Depositary Shares (jeweils gleich 13 Stammaktien) im Rahmen eines Rule 10b5-1-Plans zu Preisen zwischen 263,40 und 267,81 US-Dollar verkauft hat. Die Gesamtsumme bel盲uft sich auf etwa 0,53 Millionen US-Dollar, was etwa 0,3 % seines gesamten wirtschaftlichen Eigentums entspricht. Es wurden keine neuen Zuteilungen, Derivatgesch盲fte oder 脛nderungen in der Unternehmensf眉hrung gemeldet.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Wang Xiaodong
(Last) (First) (Middle)
C/O BEONE MEDICINES I GMBH
AESCHENGRABEN 27, 21ST FLOOR
(Street)
BASEL V8 4051
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
BeOne Medicines Ltd. [ ONC ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) X Other (specify below)
Chair, Scientific Advisory Brd
3. Date of Earliest Transaction (Month/Day/Year)
06/24/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Ordinary Shares 5,154,770 D
Ordinary Shares 1,025,063 I See Footnote(1)
Ordinary Shares 3,953,100 I See Footnote(2)
Ordinary Shares 50 I See Footnote(3)
American Depositary Shares(4) 06/24/2025 S(5) 300 D $263.5(6) 1,707 D
American Depositary Shares(4) 06/24/2025 S(5) 1,100 D $265.3525(7) 607 D
American Depositary Shares(4) 06/24/2025 S(5) 507 D $266.5653(8) 100 D
American Depositary Shares(4) 06/24/2025 S(5) 100 D $267.81 0 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. These securities are held by a family trust, the beneficiaries of which are the Reporting Person's family members, for which the Reporting Person disclaims beneficial ownership.
2. These securities are held by Wang Investment LLC, of which 99% of the limited liability company interest is owned by two grantor retained annuity trusts, of which the Reporting Person's wife is a trustee, for which the Reporting Person disclaims beneficial ownership.
3. These securities are held by the spouse of the Reporting Person.
4. Each American Depositary Share represents 13 Ordinary Shares.
5. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on August 12, 2024.
6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $263.40 to $263.55, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $265.02 to $265.86, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $266.27 to $266.95, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
Remarks:
/s/ Qing Nian, as Attorney-in-Fact 06/25/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

How many shares did ONC Director Xiaodong Wang sell in the June 2025 Form 4?

He sold 2,007 American Depositary Shares, equivalent to about 26,091 ordinary shares.

What was the total value of the ONC insider sale reported on 06/24/2025?

The transactions were valued at approximately $0.53 million based on weighted average prices of $263.40鈥�$267.81 per ADS.

Did the June 2025 Form 4 significantly change Xiaodong Wang's ownership in ONC?

No. The sale reduced his direct ADS holdings to zero but cut overall ownership by only 鈮�0.3 %.

Was the insider sale executed under a Rule 10b5-1 trading plan?

Yes. The filing states the sales were made pursuant to a 10b5-1 plan adopted on August 12, 2024.
Stock ONC logo
Beigene Ltd

NASDAQ:ONC

ONC Rankings

#367 Ranked by Market Cap
N/A Ranked by Dividends

ONC Latest News

Aug 21, 2025
European Commission Approves Tablet Formulation of BeOne Medicines鈥� BRUKINSA庐 for All Approved Indications
Aug 6, 2025
BeOne Medicines Announces Second Quarter 2025 Financial Results and Business Updates
Jul 31, 2025
BeOne Medicines Receives PRIME Designation from the European Medicines Agency for BGB-16673 in Waldenstrom鈥檚 Macroglobulinemia
Jul 28, 2025
BeOne Medicines Receives Positive CHMP Opinion for TEVIMBRA庐 in Neoadjuvant/Adjuvant NSCLC Treatment
Jul 16, 2025
BeOne Medicines to Announce Second Quarter 2025 Financial Results on August 6

ONC Latest SEC Filings

Aug 15, 2025
[Form 4] BeOne Medicines Ltd. American Insider Trading Activity
Aug 15, 2025
[Form 4] BeOne Medicines Ltd. American Insider Trading Activity
Aug 13, 2025
[144] BeOne Medicines Ltd. American SEC Filing
Aug 13, 2025
[144] BeOne Medicines Ltd. American SEC Filing
Aug 6, 2025
[10-Q] BeOne Medicines Ltd. American Quarterly Earnings Report

ONC Stock Data

37.15B
91.06M
17.24%
32.39%
1.64%
Biotechnology
Pharmaceutical Preparations
Switzerland
BASEL